Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury

Circulation

Volumn 107, Issue 19, 2003, Pages 2487-2492

  Schulze, Costas J ^a   Wang, Wenjie ^a   Suarez Pinzon, Wilma L ^a   Sawicka, Jolanta ^a   Sawicki, Grzegorz ^a   Schulz, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Inhibitors; Ischemia; Metalloproteinases; Reperfusion

Indexed keywords

CONTRACTILE PROTEIN; GELATINASE A; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TROPONIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; EFFLUENT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PERFUSION; IMMUNOGOLD ELECTRON MICROSCOPY; IN SITU ZYMOGRAPHY; ISOLATED HEART; MALE; MECHANICAL STRESS; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; RAT; REGULATORY MECHANISM; REPERFUSION INJURY; REVERSE ZYMOGRAPHY; SARCOMERE; STUNNED HEART MUSCLE; WESTERN BLOTTING; ZYMOGRAPHY;

ACUTE DISEASE; ANIMALS; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASES; MICROFILAMENTS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIUM; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; REPERFUSION INJURY; SARCOMERES; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0037841983     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000065603.09430.58     Document Type: Article

References (26)

1. Woessner JFJ. The matrix metalloproteinases family. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego, Calif: Academic Press; 1998:1-14.
2. Sawicki G, Salas E, Murat J, et al. Release of gelatinase A during platelet activation mediates aggregation. Nature. 1997;386:616-619.
3. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85:906-911.
4. Fernandez-Patron C, Stewart KG, Zhang Y, et al. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res. 2000;87:670-676.
5. McQuibban GA, Gong JH, Tam EM, et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 2000;289:1202-1206.
6. Cheung PY, Sawicki G, Wozniak M, et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 2000; 101:1833-1839.
7. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002;106:1543-1549.
8. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
9. Greene J, Wang M, Liu YE, et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem. 1996;271: 30375-30380.
10. Leco KJ, Apte SS, Taniguchi GT, et al. Murine tissue inhibitor of metalloproteinases-4 (TIMP-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett. 1997;401:213-217.
11. Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27:1281-1292.
12. Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 1998;98:1728-1734.
13. Rouet-Benzineb P, Buhler JM, Dreyfus P, et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail. 1999;1:337-352.
14. Spiess M, Steinmetz MO, Mandinova A, et al. Isolation, electron microscopic imaging, and 3-D visualization of native cardiac thin myofilaments. J Struct Biol. 1999;126:98-104.
15. Senzaki H, Paolocci N, Gluzband YA, et al. Beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ Res. 2000;86:807-815.
16. McDonough JL, Arrell DK, Van Eyk JE. Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ Res. 1999;84:9-20.
17. Morjana NA. Degradation of human cardiac troponin I after myocardial infarction. Biotechnol Appl Biochem. 1998;28:105-111.
18. Thomas SA, Fallavollita JA, Lee TC, et al. Absence of troponin I degradation or altered sarcoplasmic reticulum uptake protein expression after reversible ischemia in swine. Circ Res. 1999;85:446-456.
19. 2+ handling. Circ Res. 2001;89:831-837.
20. Gomez DE, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122.
21. Tummalapalli CM, Heath BJ, Tyagi SC. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem. 2001;80:512-521.
22. Wingfield PT, Sax JK, Stahl SJ, et al. Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. J Biol Chem. 1999;274:21362-21368.
23. YaDeau JT, Blobel G. Solubilization and characterization of yeast signal peptidase. J Biol Chem. 1989;264:2928-2934.
24. Hernandez-Barrantes S, Shimura Y, Soloway PD, et al. Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. Biochem Biophys Res Commun. 2001;281:126-130.
25. Bigg HF, Morrison CJ, Butler GS, et al. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res. 2001;61:3610-3618.
26. Mayers I, Hurst T, Puttagunta L, et al. Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts. J Thorac Cardiovasc Surg. 2001;122:746-752.